Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.
Metastatic Breast Cancer
DRUG: Amrubicin
Incidence of cardiac toxicity
Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)|Duration of overall response|Time to tumor progression|Progression free survival|Toxicity profile
The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.